Clinical values of serum cytokeratin-19 fragment in nasopharyngeal carcinoma

Yu LIU,Zhu-jian WANG,Wen-jun CAO,Xin-mao SONG,Sheng-zi WANG

DOI: https://doi.org/10.14166/j.issn.1671-2420.2018.02.011

2018-01-01

Abstract:Objective To evaluate the clinical values of serum cytokeratin-19 fragment (CYFRA21-1) for the diagnosis and prognosis of nasopharyngeal carcinoma ( NPC).Methods Electrochemiluminescence immunoassay was used to measure the serum CYFRA21-1 in untreated patients with NPC (n＝336) and in the age and sex-matched healthy control group (n＝208).One hundred NPC patients were randomly chosen and followed up, whose blood was collected before and 3 months after the treatment.Among them, the blood of 10 cases were collected before the treatment and after the 5th,10th,15th, 20th,25th and 30th radiotherapy.Results Compared with the healthy controls (2.15 ± 0.94 ng／mL), the level of serum CYFRA21-1 in the patients with NPC (4.12 ±3.23 ng／mL) was significantly elevated (t＝10.507, P＜0.001).The area of receiver operating characteristic curve (ROC curve) was 0.765(best cut-off value was 2.61, sensitivity was 63.10%, specitivity was 79.33%, P＜0.001).The level of serum CYFRA21-1 after the treatment (2.93 ±3.61ng／mL) was significantly lower than that before treatment (4.10 ±3.83 ng／mL, P＝0.020 3). And the level of serum CYFRA21-1 was in a downtrend with the increasing numbers of radiotherapies.Conclusions The level of serum CYFRA21-1 is an effective reference for the diagnosis and treatment of NPC.